Dopamine dysregulation in a mouse model of paroxysmal nonkinesigenic dyskinesia

Journal of Clinical Investigation

Volumn 122, Issue 2, 2012, Pages 507-518

  Lee, Hsien Yang ^a   Nakayama, Junko ^a,d   Xu, Ying ^a,e   Fan, Xueliang ^b   Karouani, Maha ^c   Shen, Yiguo ^a   Pothos, Emmanuel N ^c   Hess, Ellen J ^b   Fu, Ying Hui ^a   Edwards, Robert H ^a   Ptaćek, Louis J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d IBARAKI PREFECTURAL UNIVERSITY OF HEALTH SCIENCES   (Japan)

^e NANJING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; CAFFEINE; DOPAMINE; PROTEIN C FOS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASAL GANGLION; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE RELEASE; DYSKINESIA; GENE; GENE EXPRESSION; GENE LOCUS; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NERVE CELL; NEUROTRANSMISSION; NONHUMAN; PAROXYSMAL NONKINESIGENIC DYSKINESIA; PATHOPHYSIOLOGY; PHENOTYPE; PNKD GENE; PRIORITY JOURNAL; REST; STRESS;

AMINO ACID SEQUENCE; ANIMALS; CHOREA; CORPUS STRIATUM; DOPAMINE; DOPAMINE UPTAKE INHIBITORS; HEK293 CELLS; HUMANS; MICE; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; MUSCLE PROTEINS; MUTATION; NOMIFENSINE; PHENOTYPE;

EID: 84863011960     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI58470     Document Type: Article

References (53)

1. Demirkiran M, Jankovic J. Paroxysmal dyskinesias: clinical features and classification. Ann Neurol. 1995;38(4):571-579.
2. Tarsy D, Simon DK. Dystonia. N Engl J Med. 2006;355(8):818-829. (Pubitemid 44285587)
3. Bruno MK, et al. Genotype-phenotype correlation of paroxysmal nonkinesigenic dyskinesia. Neurology. 2007;68(21):1782-1789. (Pubitemid 46791390)
4. Fink JK, et al. Paroxysmal dystonic choreoathetosis: tight linkage to chromosome 2q. Am J Hum Genet. 1996;59(1):140-145. (Pubitemid 26189739)
5. Fouad GT, Servidei S, Durcan S, Bertini E, Ptacek LJ. A gene for familial paroxysmal dyskinesia (FPD1) maps to chromosome 2q. Am J Hum Genet. 1996;59(1):135-139. (Pubitemid 26189738)
6. Chen DH, et al. Presence of alanine-to-valine substitutions in myofibrillogenesis regulator 1 in paroxysmal nonkinesigenic dyskinesia: confirmation in 2 kindreds. Arch Neurol. 2005;62(4):597-600.
7. Lee HY, et al. The gene for paroxysmal non-kinesigenic dyskinesia encodes an enzyme in a stress response pathway. Hum Mol Genet. 2004;13(24):3161-3170.
8. Stefanova E, et al. Clinical characteristics of paroxysmal nonkinesigenic dyskinesia in Serbian family with Myofibrillogenesis regulator 1 gene mutation. Mov Disord. 2006;21(11):2010-2015.
9. Rainier S, et al. Myofibrillogenesis regulator 1 gene mutations cause paroxysmal dystonic choreoathetosis. Arch Neurol. 2004;61(7):1025-1029. (Pubitemid 38915943)
10. Hempelmann A, Kumar S, Muralitharan S, Sander T. Myofibrillogenesis regulator 1 gene (MR-1) mutation in an Omani family with paroxysmal nonkinesigenic dyskinesia. Neurosci Lett. 2006;402(1-2):118-120. (Pubitemid 43766449)
11. Ghezzi D, et al. Paroxysmal non-kinesigenic dyskinesia is caused by mutations of the MR-1 mitochondrial targeting sequence. Hum Mol Genet. 2009;18(6):1058-1064.
12. Thornalley PJ. Pharmacology of methylglyoxal: formation, modification of proteins and nucleic acids, and enzymatic detoxification - a role in pathogenesis and antiproliferative chemotherapy. Gen Pharmacol. 1996;27(4):565-573. (Pubitemid 26233322)
13. Fisone G, Hakansson K, Borgkvist A, Santini E. Signaling in the basal ganglia: postsynaptic and presynaptic mechanisms. Physiol Behav. 2007;92(1-2):8-14. (Pubitemid 47376895)
14. Surmeier DJ, Ding J, Day M, Wang Z, Shen W. D1 and D2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons. Trends Neurosci. 2007;30(5):228-235. (Pubitemid 46654239)
15. Werkman TR, Glennon JC, Wadman WJ, McCreary AC. Dopamine receptor pharmacology: interactions with serotonin receptors and significance for the aetiology and treatment of schizophrenia. CNS Neurol Disord Drug Targets. 2006;5(1):3-23. (Pubitemid 43796625)
16. Bolam JP, Hanley JJ, Booth PA, Bevan MD. Synaptic organisation of the basal ganglia. J Anat. 2000;196(pt 4):527-542. (Pubitemid 30458775)
17. Mink JW. The basal ganglia: focused selection and inhibition of competing motor programs. Prog Neurobiol. 1996;50(4):381-425. (Pubitemid 27028538)
18. Smith Y, Bevan MD, Shink E, Bolam JP. Microcircuitry of the direct and indirect pathways of the basal ganglia. NeuroScience. 1998;86(2):353-387. (Pubitemid 28293917)
19. Lundstrom K, Salminen M, Jalanko A, Savolainen R, Ulmanen I. Cloning and characterization of human placental catechol-O-methyltransferase cDNA. DNA Cell Biol. 1991;10(3):181-189.
20. Schiffmann SN, Fisone G, Moresco R, Cunha RA, Ferre S. Adenosine A2A receptors and basal ganglia physiology. Prog Neurobiol. 2007;83(5):277-292. (Pubitemid 350110609)
21. Schwarzschild MA, Agnati L, Fuxe K, Chen JF, Morelli M. Targeting adenosine A2A receptors in Parkinson's disease. Trends Neurosci. 2006;29(11):647-654. (Pubitemid 44602262)
22. Fuxe K, Ferre S, Genedani S, Franco R, Agnati LF. Adenosine receptor-dopamine receptor interactions in the basal ganglia and their relevance for brain function. Physiol Behav. 2007;92(1-2):210-217. (Pubitemid 47381380)
23. Ferre S, Fredholm BB, Morelli M, Popoli P, Fuxe K. Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci. 1997;20(10):482-487. (Pubitemid 27421712)
24. Kim DS, Palmiter RD. Interaction of dopamine and adenosine receptor function in behavior: studies with dopamine-deficient mice. Front Biosci. 2008;13:2311-2318. (Pubitemid 351589256)
25. Fisone G, Borgkvist A, Usiello A. Caffeine as a psychomotor stimulant: mechanism of action. Cell Mol Life Sci. 2004;61(7-8):857-872. (Pubitemid 38659659)
26. Ferre S. An update on the mechanisms of the psychostimulant effects of caffeine. J Neurochem. 2008;105(4):1067-1079. (Pubitemid 351590775)
27. Xie X, Ramkumar V, Toth LA. Adenosine and dopamine receptor interactions in striatum and caffeine-induced behavioral activation. Comp Med. 2007;57(6):538-545.
28. Watanabe H, Uramoto H. Caffeine mimics dopamine receptor agonists without stimulation of dopamine receptors. Neuropharmacology. 1986;25(6):577-581. (Pubitemid 16056521)
29. Morgan ME, Vestal RE. Methylxanthine effects on caudate dopamine release as measured by in vivo electrochemistry. Life Sci. 1989;45(21):2025-2039. (Pubitemid 19277497)
30. Kirch DG, Taylor TR, Gerhardt GA, Benowitz NL, Stephen C, Wyatt RJ. Effect of chronic caffeine administration on monoamine and monoamine metabolite concentrations in rat brain. Neuropharmacology. 1990;29(6):599-602. (Pubitemid 20194700)
31. Reggiani A, Barbaccia ML, Spano PF, Trabucchi M. Dopamine metabolism and receptor function after acute and chronic ethanol. J Neurochem. 1980;35(1):34-37. (Pubitemid 10063203)
32. Barbaccia ML, Bosio A, Spano PF, Trabucchi M. Ethanol metabolism and striatal dopamine turnover. J Neural Transm. 1982;53(2-3):169-177. (Pubitemid 12187308)
33. Breakefield XO, Blood AJ, Li Y, Hallett M, Hanson PI, Standaert DG. The pathophysiological basis of dystonias. Nat Rev Neurosci. 2008;9(3):222-234. (Pubitemid 351272666)
34. Hamann M, Richter A. Striatal increase of extracellular dopamine levels during dystonic episodes in a genetic model of paroxysmal dyskinesia. Neurobiol Dis. 2004;16(1):78-84. (Pubitemid 38569798)
35. Clot F, et al. Exhaustive analysis of BH4 and dopamine biosynthesis genes in patients with Dopa-responsive dystonia. Brain. 2009;132(pt 7):1753-1763.
36. Segawa M. Dopa-responsive dystonia. Handb Clin Neurol. 2011;100:539-557.
37. Marin C, Aguilar E, Mengod G, Cortes R, Obeso JA. Concomitant short- and long-duration response to levodopa in the 6-OHDA-lesioned rat: a behavioural and molecular study. Eur J Neurosci. 2007;25(1):259-269. (Pubitemid 46098896)
38. Paille V, Henry V, Lescaudron L, Brachet P, Damier P. Rat model of Parkinson's disease with bilateral motor abnormalities, reversible with levodopa, and dyskinesias. Mov Disord. 2007;22(4):533-539. (Pubitemid 46608152)
39. Zigmond MJ, Berger TW, Grace AA, Stricker EM. Compensatory responses to nigrostriatal bundle injury. Studies with 6-hydroxydopamine in an animal model of parkinsonism. Mol Chem Neuropathol. 1989;10(3):185-200. (Pubitemid 19204706)
40. Breese GR, Knapp DJ, Criswell HE, Moy SS, Papadeas ST, Blake BL. The neonate-6-hydroxydopamine-lesioned rat: a model for clinical neuroscience and neurobiological principles. Brain Res Brain Res Rev. 2005;48(1):57-73. (Pubitemid 40215783)
41. Fan X, Bruno KJ, Hess EJ. Rodent models of ADHD [published online ahead of print March 15, 2011]. Curr Top Behav Neurosci. doi:10.1007/7854-2011-121.
42. Masuo Y, Morita M, Oka S, Ishido M. Motor hyperactivity caused by a deficit in dopaminergic neurons and the effects of endocrine disruptors: a study inspired by the physiological roles of PACAP in the brain. Regul Pept. 2004;123(1-3):225-234. (Pubitemid 39424171)
43. Kreitzer AC, Malenka RC. Striatal plasticity and basal ganglia circuit function. Neuron. 2008;60(4):543-554.
44. van der Stelt M, Di Marzo V. The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders. Eur J Pharmacol. 2003;480(1-3):133-150. (Pubitemid 37410366)
45. Shen W, Flajolet M, Greengard P, Surmeier DJ. Dichotomous dopaminergic control of striatal synaptic plasticity. Science. 2008;321(5890):848-851.
46. Kreitzer AC, Malenka RC. Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models. Nature. 2007;445(7128):643- 647. (Pubitemid 46232883)
47. Maher PA, Singer SJ. Anomalous interaction of the acetylcholine receptor protein with the nonionic detergent Triton X-114. Proc Natl Acad Sci U S A. 1985;82(4):958-962. (Pubitemid 15100473)
48. Wetterhall M, Shevchenko G, Artemenko K, Sjodin MO, Bergquist J. Analysis of membrane and hydrophilic proteins simultaneously derived from the mouse brain using cloud-point extraction. Anal Bioanal Chem. 2011;400(9):2827-2836.
49. Page ME, Brown K, Lucki I. Simultaneous analyses of the neurochemical and behavioral effects of the norepinephrine reuptake inhibitor reboxetine in a rat model of antidepressant action. Psychopharmacology (Berl). 2003;165(2):194-201. (Pubitemid 36056997)
50. Sulzer D, Edwards R. Vesicles: equal in neurotransmitter concentration but not in volume. Neuron. 2000;28(1):5-7.
51. Goldberg MS, et al. Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial Parkinsonism-linked gene DJ-1. Neuron. 2005;45(4):489-496. (Pubitemid 40249861)
52. Richter A, Loscher W. Pathology of idiopathic dystonia: findings from genetic animal models. Prog Neurobiol. 1998;54(6):633-677. (Pubitemid 28137702)
53. Wang JQ, McGinty JF. The full D1 dopamine receptor agonist SKF-82958 induces neuropeptide mRNA in the normosensitive striatum of rats: regulation of D1/D2 interactions by muscarinic receptors. J Pharmacol Exp Ther. 1997;281(2):972-982. (Pubitemid 27203834)